Concentration-response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy.

ABSTRACT: Dolutegravir is associated with more weight gain than efavirenz in people starting antiretroviral therapy (ART). We investigated the concentration-response relationships of efavirenz and dolutegravir with weight gain. We determined concentration-response relationships of dolutegravir and efavirenz (both combined with tenofovir disoproxil fumarate and emtricitabine) with changes in weight and fat distribution, derived from dual-energy x-ray absorptiometry scans, in a nested study of ART-naïve participants from a randomised controlled trial. Pharmacokinetic parameters used in analyses were efavirenz mid-dosing interval concentrations and estimated dolutegravir area under the concentration-time curve using a population pharmacokinetic model developed in the study population. Study outcomes we

SUBMITTER: Griesel R 

PROVIDER: S-EPMC7612404 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature